Search research articles
Contact Us
Filters
Showing results (21-30 of 69) with videos related to
Page
of 7
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 4, 2015
Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis
Annette D Fialla, Mads Israelsen, Ole Hamberg, et al.
Trials
|
February 28, 2018
Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial
Bjørn Stæhr Madsen, Jonel Trebicka, Maja Thiele, et al.
Hepatology (Baltimore, Md.)
|
October 6, 2023
Noninvasive assessment of hepatic decompensation
Maja Thiele, Stine Johansen, Mads Israelsen, et al.
Annals of Hepatology
|
July 3, 2025
Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE
Nikolaj Torp, Louise China, Mads Israelsen, et al.
The Cochrane Database of Systematic Reviews
|
September 28, 2017
Terlipressin versus other vasoactive drugs for hepatorenal syndrome
Mads Israelsen, Aleksander Krag, Andrew S Allegretti, et al.
World Journal of Gastroenterology
|
April 25, 2018
Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients
Agnete Nordheim Riedel, Nina Kimer, Anne-Sofie Houlberg Jensen, et al.
Journal of Hepatology
|
June 12, 2021
Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease
Ditlev Nytoft Rasmussen, Maja Thiele, Stine Johansen, et al.
The Cochrane Database of Systematic Reviews
|
June 27, 2018
Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Andrew S Allegretti, Mads Israelsen, Aleksander Krag, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
December 17, 2019
Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial
Mads Israelsen, Emilie Kristine Dahl, Bjørn Stæhr Madsen, et al.
BMJ Open
|
February 14, 2024
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial
Nikolaj Torp, Mads Israelsen, Minneke Coenraad, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 69) with videos related to
Sort By:
Page
of 7
Liver International : Official Journal of the International Association for the Study of the Liver
|
February 4, 2015
Nutritional therapy in cirrhosis or alcoholic hepatitis: a systematic review and meta-analysis
Annette D Fialla, Mads Israelsen, Ole Hamberg, et al.
Trials
|
February 28, 2018
Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial
Bjørn Stæhr Madsen, Jonel Trebicka, Maja Thiele, et al.
Hepatology (Baltimore, Md.)
|
October 6, 2023
Noninvasive assessment of hepatic decompensation
Maja Thiele, Stine Johansen, Mads Israelsen, et al.
Annals of Hepatology
|
July 3, 2025
Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE
Nikolaj Torp, Louise China, Mads Israelsen, et al.
The Cochrane Database of Systematic Reviews
|
September 28, 2017
Terlipressin versus other vasoactive drugs for hepatorenal syndrome
Mads Israelsen, Aleksander Krag, Andrew S Allegretti, et al.
World Journal of Gastroenterology
|
April 25, 2018
Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients
Agnete Nordheim Riedel, Nina Kimer, Anne-Sofie Houlberg Jensen, et al.
Journal of Hepatology
|
June 12, 2021
Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease
Ditlev Nytoft Rasmussen, Maja Thiele, Stine Johansen, et al.
The Cochrane Database of Systematic Reviews
|
June 27, 2018
Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome
Andrew S Allegretti, Mads Israelsen, Aleksander Krag, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
December 17, 2019
Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial
Mads Israelsen, Emilie Kristine Dahl, Bjørn Stæhr Madsen, et al.
BMJ Open
|
February 14, 2024
Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial
Nikolaj Torp, Mads Israelsen, Minneke Coenraad, et al.
Page
of 7